Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.
|Articles|April 24, 1996
Peptide firm Diatide to go public
Peptide imaging agent developer Diatide of Londonderry, NH, planson issuing an initial public offering in the next several weeksthat will raise $25 million to fund ongoing product development.The firm will price its stock at $10 to $12 a share,
Advertisement
Peptide imaging agent developer Diatide of Londonderry, NH, plans
on issuing an initial public offering in the next several weeks
that will raise $25 million to fund ongoing product development.
The firm will price its stock at $10 to $12 a share, according
to president Richard Dean. Diatide's lead product is a technetium-99m-labeled
agent for detection of deep vein thrombosis.
Advertisement
Related to this article
Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
2
Could Photon-Counting CT Have an Impact as a Platform for Molecular Imaging?
3
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
4
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
5